Status:

COMPLETED

Radiofrequency Ablation of Lung Tumors

Lead Sponsor:

Gustave Roussy, Cancer Campus, Grand Paris

Conditions:

Lung Cancer

Metastasis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

Radiofrequency ablation has achieved impressive results in the treatment of unresectable primary and metastatic liver cancer. Animal studies have demonstrated that radiofrequency can fully ablate lung...

Detailed Description

Radiofrequency (RF) ablation has achieved impressive results in the treatment of unresectable primary and metastatic liver cancer. Animal studies have demonstrated that RF can fully ablate lung tumors...

Eligibility Criteria

Inclusion

  • Unilateral or bilateral unresectable primary or metastatic lung tumors \<= 40 mm and a number of tumor \<=5
  • Tumors located more than 1 cm from the hilum, and not involving soft tissues or mediastinum.
  • Malignancy histologically proven for pulmonary nodules in patients with no history of cancer outside the lung.
  • Lung tumors in patients with a known distant cancer history, has to be either histologically proven or a demonstrated change in size of at least 25% in their largest diameter is required on CT during the previous year
  • Pretreatment imaging work-up within 4 weeks of scheduled RF ablation (at least a chest CT and an abdomino-pelvic CT)
  • If a tumor is found outside the lung, it has to be amenable to complete eradication with RF or RF plus surgery
  • Lung spirometry within 4 weeks of treatment with a FEV1 \>= 1 liter
  • Written informed consent.

Exclusion

  • Uncorrectable coagulopathy with a prothrombin time greater than 1.5 and a platelet count below 106/mm3

Key Trial Info

Start Date :

January 1 2002

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT00180856

Start Date

January 1 2002

Last Update

September 16 2005

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Institut Bergonié

Bordeaux, France, 33 000

2

Institut Gustave Roussy

Villejuif, France, 94800